An anti-HIV strategy combining chemotherapy and therapeutic vaccination

Journal of Medical Primatology

Volumn 28, Issue 4-5, 1999, Pages 195-205

  Rosenwirth, B ^a   Bogers, W M J M ^a   Nieuwenhuis, I G ^a   Ten Haaft, P ^a   Niphuis, H ^a   Kuhn, E M ^a   Bischofberger, N ^b   Erfle, V ^c   Sutter, G ^c   Berglund, P ^d   Liljestrom, P ^d,e   Uberla, K ^f   Heeney, J L ^a  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b GILEAD SCIENCES   (United States)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d KAROLINSKA INSTITUTE   (Sweden)

^e SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^f UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Anti retroviral therapy; Macaques; PMPA; SHIV; Vaccines

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DRUG DERIVATIVE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; METHYLPHOSPHONIC ACID PINACOLYL ESTER; SOMAN; VIRUS ENVELOPE PROTEIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHIMERA; DISEASE MODEL; GENE VECTOR; GENETICS; HOMEOBOX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MACACA; MONKEY DISEASE; MULTIMODALITY CANCER THERAPY; SEMLIKI FOREST ALPHAVIRUS; VACCINATION; VACCINIA VIRUS; VIRUS LOAD;

AIDS VACCINES; ANIMALS; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CHIMERA; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; GENES, HOMEOBOX; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; MACACA MULATTA; SEMLIKI FOREST VIRUS; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SOMAN; VACCINATION; VACCINIA VIRUS; VIRAL ENVELOPE PROTEINS; VIRAL LOAD;

EID: 0033174082     PISSN: 00472565     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0684.1999.tb00270.x     Document Type: Review

References (39)

1. + T cell homeostasis and function in advanced HIV disease. Science 277:112-116, 1997.
2. BALZARINI J, HOLY A, JINDRICH J, NAESENS L, SNOECK R, SCHOLS D, DE CLERCQ E: Differential antiherpesvirus and antiretrovirus effects of the (S) and (R) enantiomers of acyclic nucleoside phosphonates: Potent and selective in vitro and in vivo antiretrovirus activities of (R)-9-(2-phosphonomethoxypropyl)-2,6-diaminopurine. Antimicrob Agents Chemother 37:332-338, 1993.
3. BALZARINI J, AQUARO S, PERNO CF, WITVROUW M, HOLY A, DE-CLERCQ E: Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochem Biophys Res Commun 219:331-341, 1996.
4. BARDITCH-CROVO P, TOOLE J, HENDRIX C W, CUNDY KC, EBELING D, JAFFE HS, LIETMAN PS: Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. J Infect Dis 176:406-413, 1997.
5. BODEN D, MARKOWITZ M: Resistance to human immunodeficiency virus type 1 protease inhibitors. Antimicrob Agents Chemother 42:2775-2783, 1998.
6. CALAROTA S, BRATT G, NORDLUND S, HINKULA J, LEANDERSSON AC, SANDSTROM E, WAHREN B: Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 351:1320-1325, 1998.
7. CARPENTER CC, FISCHL MA, HAMMER SM, HIRSCH MS, JACOBSEN DM, KATZENSTEIN DA, MONTANER JS, RICHMAN DD, SAAG MS, SCHOOLEY RT, THOMPSON MA, VELLA S, YENI PG, VOLBERDING PA: Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel. JAMA 280:78-86, 1998.
8. AIDS CLINICAL TRIALS GROUP, COLLIER AC, COOMBS RW, SCHOENFELD DA, BASSETT RL, TIMPONE J, BARUCH A, JONES M, FACEY K, WHITACRE C, MCAULIFFE VJ, FRIEDMAN HM, MERIGAN TC, REICHMAN RC, HOOPER C, COREY L: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. N Engl J Med 334:1011-1017, 1996.
9. DEEKS SG, BARDITCH-CROVO P, LIETMAN PS, HWANG F, CUNDY KC, ROONEY JF, HELLMANN NS, SAFRIN S, KAHN JO: Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother 42:2380-2384, 1998.
10. + repertoire during antiviral therapy. Nat Med 4:215-221, 1998.
11. GULICK RM, MELLORS JW, HAVLIR D, ERON JJ, GONZALEZ C, MCMAHON D, RICHMAN DD, VALENTINE FT, JONAS L, MEIBOHM A, EMINI EA, CHODAKEWITZ JA: Treatment with indinavir, zidovudine, and lamivudine in adults with human, immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337:734-739, 1997.
12. HAMMER SM, SQUIRES KE, HUGHES MD, GRIMES JM, DEMETER LM, CURRIER JS, ERON JJ, JR, FEINBERG JE, BALFOUR HH, JR, DEYTON LR, CHODAKEWITZ JA, FISCHL MA: A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimetre or less. N Engl J Med 337:725-733, 1997.
13. AIDS CLINICAL TRIALS GROUP STUDY 175 VIROLOGY STUDY TEAM, KATZENSTEIN DA, HAMMER SM, HUGHES MD, GUNDACKER H, JACKSON JB, FISCUS S, RASHEED S, ELBEIK T, REICHMAN R, JAPOUR A, MERIGAN TC, HIRSCH MS: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimetre [see comments]. N Engl J Med 335:1091-1098, 1996. Published erratum appears in N End J Med 337 (15):1097, 1997.
14. COMMUNITY HIV RESEARCH NETWORK INVESTIGATORS, KELLEHER AD, ROGGENSACK M, JARAMILLO AB, SMITH DE, WALKER A, GOW I, MCMURCHIE M, HARRIS J, PATOU G, COOPER DA: Safety and immunogenicity of a candidate therapeutic vaccine, p24 virus-like particle, combined with zidovudine, in asymptomatic subjects. AIDS 12:175-182, 1998.
15. KLEIN MR, VEENSTRA J, HOLWERDA AM, ROOS MT, GOW I, PATOU G, COUTINHO RA, DE WOLF F, MIEDEMA F: Gag-specific immune responses after immunization with p17/p24:Ty virus-like particles in HIV type 1-seropositive individuals. AIDS Res Hum Retroviruses 13:393-399, 1997.
16. KUNDU SK, KATZENSTEIN D, VALENTINE FT, SPINO C, EFRON B, MERIGAN TC: Effect of therapeutic immunization with recombinant gp 160 HIV-1 vaccine on HIV-1 proviral DNA and plasma RNA: Relationship to cellular immune responses. J Acquir Immune Defic Syndr Hum Retrovirol 15:269-274, 1997.
17. LI TS, TUBIANA R, KATLAMA C, CALVEZ V, AIT MOHAND H, AUTRAN B: Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 351:1682-1686, 1998.
18. MATHEZ D, BAGNARELLI P, GORIN I, KATLAMA C, PIALOUX G, SAIMOT G, TUBIANA P, DE TRUCHIS P, CHAUVIN J-P, MILLS R, RODE R, CLEMENTI M, LEIBOWITCH J: Reductions in viral load and increases in T lymphocyte numbers in treatment-naive patients with advanced HIV-1 infection treated with ritonavir, zidovudine and zalcitabine triple therapy. Antiviral Ther 2:175-183, 1997.
19. MELLORS JW, RINALDO CR, JR, GUPTA P, WHITE RM, TODD JA, KINGSLEY LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272:1167-1170, 1996.
20. MORRIS-JONES S, MOYLE G, EASTERBROOK PJ: Antiretroviral therapies in HIV-1 infection. Exp Opin Invest Drugs 6:1049-1061, 1997.
21. MOSS RB, GIERMAKOWSKA W, LANZA P, TURNER JL, WALLACE MR, JENSEN FC, THEOFAN G, RICHIERI SP, CARLO DJ: Cross-clade immune responses after immunization with a whole-killed gp 120-depleted human immunodeficiency virus type-1 immunogen in incomplete Freund's adjuvant (HIV-1 immunogen, REMUNE) in human immunodeficiency virus type-1 seropositive subjects. Viral Immunol 10:221-228, 1997.
22. MOSS RB, WALLACE MR, LANZA P, GIERMAKOWSKA W, JENSEN FC, THEOFAN G, CHAMBERLIN C, RICHIERI SP, CARLO DJ: In vitro p24 antigen-stimulated lymphocyte proliferation and beta-chemokine production in human immunodeficiency virus type 1 (HIV-1)seropositive subjects after immunization with an inactivated gp120-depleted HIV-1 immunogen (Remune). Clin Diagn Lab Immunol 5:308-312, 1998.
23. MOYLE GJ: Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice. Exp Opin Invest Drugs 6:943-964, 1997.
24. PAKKER NG, NOTERMANS DW, DE BOER RJ, ROOS MT, DE WOLF F, HILL A, LEONARD JM, DANNER SA, MIEDEMA F, SCHELLEKENS PT: Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: A composite of redistribution and proliferation. Nat Med 4:208-214, 1999.
25. PERELSON AS, ESSUNGER P, CAO Y, VESANEN M, HURLEY A, SAKSELA K, MARKOWITZ M, HO DD: Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 387:188-191, 1997.
26. PETERS BS, CHEINGSONG-POPOV R, CALLOW D, FOXALL R, PATOU G, HODGKIN K, WEBER JN: A pilot phase II study of the safety and immunogenicity of HIV p17/ p24:VLP (p24-VLP) in asymptomatic HIV seropositive subjects. J Infect 35:231-235, 1997.
27. RIDDLER SA, MELLORS JW: HIV-1 viral load and clinical outcome: Review of recent studies. AIDS 11:S141-148, 1997.
28. SCHINAZI RF, LARDER BA, MELLORS JW: Mutations in retroviral genes associated with drug resistance. Int Antiviral News 4:95-107, 1996.
29. SMERDOU C, LILJESTROM P: Two-helper RNA, system for production of recombinant semliki forest virus particles. J Virol 73:1092-1098, 1999.
30. TEN HAAFT P, VERSTREPEN B, UBERLA K, ROSENWIRTH B, HEENEY JL: A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J Virol 72:10281-10285, 1998.
31. TSAI CC, FOLLIS KE, SABO A, BECK TW, GRANT RF, BISCHOFBERGER N, BENVENISTE RE, BLACK R: Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science 270:1197-1199, 1995.
32. TSAI CC, FOLLIS KE, BECK TW, SABO A, BISCHOFBERGER N, DAILEY PJ: Effects of (R)-9(2-phosphonylmethoxypropyl)adenine, monotherapy on chronic SIV infection in macaques. AIDS Res Hum Retroviruses 13:707-712, 1997.
33. TSAI CC, EMAU P, FOLLIS KE, BECK TW, BENVENISTE RE, BISCHOFBERGER N, LIFSON JD, MORTON WR: Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 72:4265-4273, 1998.
34. UBERLA K, STAHL-HENNIG C, BOTTIGER D, MATZRENSING K, KAUF FJ, LI J, HASELTINE WA, FLECKENSTEIN B, HUNSMANN G, OBERG B, SODROSKI J: Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci USA 92:8210-8214, 1995.
35. UGEN KE, BOYER JD, WANG B, BAGARAZZI M, JAVADIAN A, FROST P, MERVA MM, AGADJANYAN MG, NYLAND S, WILLIAMS WV, CONEY L, CICCARELLI R, WEINER DB: Nucleic acid immunization of chimpanzees as a prophylactic/immunotherapeutic vaccination model for HIV-1: Prelude to a clinical trial. Vaccine 15:927-930, 1997.
36. 3 CD4 T lymphocytes. J Infect Dis 173:1336-1346, 1999.
37. VAN ROMPAY KK, CHERRINGTON JM, MARTHAS ML, BERARDI CJ, MULATO AS, SPINNER A, TARARA RP, CANFIELD DR, TELM S, BISCHOFBERGER N, PEDERSEN NC: 9-[2(phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother 40:2586-2591, 1996.
38. VAN ROMPAY KK, BERARDI CJ, AGUIRRE NL, BISCHOFBERGER N, LIETMAN PS, PEDERSEN NC, MARTHAS ML: Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS 12:F79-83, 1998.
39. VAN ROMPAY KK, MARTHAS ML, LIFSON JD, BERARDI CJ, VASQUEZ GM, AGATEP E, DEHQANZADA ZA, CUNDY KC, BISCHOFBERGER N, PEDERSEN NC: Administration of 9-[2(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res Hum Retroviruses 14:761-773, 1998.